Melbourne, Australia; Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is one of 20 Australian companies, and one of only two Biotechs, selected to present at the third annual ASX Small to Mid Caps conference in Hong Kong.

Watch the presentation

The ASX Hong Kong conference is part of a series of international investor events designed to showcase emerging Australian small and mid-cap listed companies to investors in Asia, Europe and the US.  In May 2010, Starpharma participated in a similar ASX event in Singapore.

Presenting to more than 195 international investors, Starpharma CEO Dr Jackie Fairley will outline the Company’s lead pharmaceutical development, VivaGel^® – a microbicide gel for the prevention of sexually transmitted infections (STIs) including HIV and genital herpes, and the Company’s major deal with SSL International plc – together with the wider range of applications for its dendrimer technology platform including agrochemicals and drug delivery.

Dr Fairley’s presentation details recent developments in Starpharma’s clinical trial program and partnering activities, including a range of commercial partnerships with major companies including Lilly, SSL International, Siemen’s Healthcare, GSK and Elanco.  A copy of Dr Fairley’s slide presentation is attached.

The ASX conference involves emerging Australian companies with market capitalisations of up to AU$1.6 billion, and a combined market cap of approximately AU$11.76 billion.

In addition, Starpharma is this week participating in the AusBiotech National Conference in Melbourne and attended by companies such as Merck, GlaxoSmithKline, Roche and Pfizer.

Dr Fairley presented to more than 150 investors at the Australasian Life Science Investment Summit ahead of the conference, and other executives of the company are actively involved in partnering discussions with a number of delegates over the next few days.